Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis.
The relative efficacy of different strategies for chronic hepatitis B (CHB) patients with lamivudine resistance (LAM-R) has not yet been systematically studied. Clinical trials were searched in PUBMED, MEDLINE, EMBASE, and CNKI databases up to February 15, 2016. Nine trials including 764 patients met the entry criteria. In direct meta-analysis, TDF showed a stronger antiviral effect than any one of ETV, LAM/ADV, and ADV against LAM-R hepatitis B virus. LAM/ADV therapy was superior to ADV in suppressing viral replication. ETV achieved similar rate of HBV DNA undetectable compared to ADV or LAM/ADV. In network meta-analysis, TDF had higher rates of HBV DNA undetectable compared to ETV (OR, 24.69; 95% CrI: 5.36-113.66), ADV (OR, 37.28; 95% CrI: 9.73-142.92), or LAM/ADV (OR, 21.05; 95% CrI: 5.70-77.80). However, among ETV, ADV, and LAM/ADV, no drug was clearly superior to others in HBV DNA undetectable rate. Moreover, no significant difference in the rate of ALT normalization or HBeAg loss was observed compared the four rescue strategies with each other. TDF appears to be a more effective rescue therapy than LAM/ADV, ETV, or ADV. LAM plus ADV therapy was a better treatment option than ETV or ADV alone for patients with LAM-R.
Department of Genetics and Molecular Biology, Xi'an Jiaotong University School of Medicine, Xi'an, Shaanxi 710061, China; Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education, Xi'an, Shaanxi 710061, China.
Hui-Lian
0000-0003-4719-6306
HL
Wang
School of Mechanical Engineering, Xi'an Jiaotong University, Xi'an, Shaanxi 710049, China.
Xi
X
Lu
Department of Genetics and Molecular Biology, Xi'an Jiaotong University School of Medicine, Xi'an, Shaanxi 710061, China; Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education, Xi'an, Shaanxi 710061, China.
Xudong
X
Yang
2nd Affiliated Hospital, Xi'an Jiaotong University School of Medicine, Xi'an, Shaanxi 710004, China.
Nan
N
Xu
Hepatology. 2006 Jun;43(6):1385-91
16729316
Virol J. 2009 Oct 09;6:163
19818142
Dig Dis Sci. 2011 Jul;56(7):2130-6
21253834
Virus Genes. 2014 Feb;48(1):32-7
24203098
Hepatology. 2007 Feb;45(2):507-39
17256718
Clin Mol Hepatol. 2014 Sep;20(3):267-73
25320730
Hepatol Int. 2008 Jun;2(2):244-9
19669311
J Viral Hepat. 2010 Mar;17(3):171-7
19678894
J Hepatol. 2009 Feb;50(2):227-42
19054588
Aliment Pharmacol Ther. 2011 Oct;34(8):972-81
21883327
J Med Virol. 2010 Nov;82(11):1835-42
20872709
Arab J Gastroenterol. 2014 Mar;15(1):1-5
24630505
Hepatology. 2009 May;49(5 Suppl):S112-21
19399795
Hepatogastroenterology. 2012 Mar-Apr;59(114):477-80
21940383
Hepatol Int. 2012 Jun;6(3):531-61
26201469
Hepatology. 2014 Feb;59(2):434-42
23939953
Korean J Intern Med. 2015 Jan;30(1):32-41
25589833
Antimicrob Agents Chemother. 2013 Apr;57(4):1790-6
23380725
J Hepatol. 2012 Jul;57(1):167-85
22436845
J Gastroenterol Hepatol. 2010 Aug;25(8):1374-80
20659226
Clin Ther. 2013 Dec;35(12):1997-2006
24238791
Ann Intern Med. 2013 Jul 16;159(2):130-7
23856683
PLoS One. 2014 Jun 06;9(6):e98865
24905092
Hepatol Int. 2008 Sep;2(3):263-83
19669255
J Hepatol. 2006 Feb;44(2):283-90
16338024
Hepatology. 2007 Feb;45(2):307-13
17256746
World J Gastroenterol. 2015 Mar 7;21(9):2746-53
25759545
Gastroenterology. 2003 Dec;125(6):1714-22
14724824